Gina Mauro | Authors


Trilaciclib Reduces Need for Supportive Care Interventions from Chemo-Induced AEs in ES-SCLC

October 21, 2020

Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.

AUTO3, Pembrolizumab Combo Appears Safe, Elicits Durable Responses in Relapsed/Refractory DLBCL

September 27, 2020

Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Balstilimab Monotherapy, Combination Shows Promise in Recurrent/Metastatic Cervical Cancer

September 25, 2020

Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.

Study Sees Encouraging Responses with Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

September 24, 2020

“Results from this study suggest that tisotumab vedotin has the potential to be a new therapy for patients with previously treated recurrent and/or metastatic cervical cancer,” said lead study author Robert L. Coleman, MD, FACOG, FACS.